ArticleScientific reports2025
Quantitative analysis of drug-drug interactions among active components of Xuebijing in inhibiting LPS-induced TLR4 signaling and NO production.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hydroxysafflor yellow A attenuates sepsis-induced intestinal barrier dysfunction by modulating Bcl-2/SOD2-mediated mitochondrial apoptosis.Frontiers in pharmacology · 2026Article
- Mapping the Global Research on Drug-Drug Interactions: A Multidecadal Evolution Through AI-Driven Terminology Standardization.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the long history of Traditional Chinese Medicine (TCM) in disease treatment, the underlying "Jun-Chen-Zuo-Shi" principle remains largely unexplored. To address this gap, it is essential to elucidate the interactions between active substances in TCM through quantitative molecular and cellular pharmacology. The Chou-Talalay method is particularly effective for investigating drug combinations, making it highly relevant for TCM formulas. This study employed the Chou-Talalay method to explore the drug-drug interactions in Xuebijing (XBJ), a TCM formula used for treating sepsis. The aim was to elucidate the "Jun-Chen-Zuo-Shi" principle by investigating the interactions of the main active substances in XBJ: danshensu and salvianolic acid B (from Radix Salviae Miltiorrhizae), senkyunolide A (from Rhizoma Chuanxiong), ligustilide (from Radix Angelicae Sinensis), safflower yellow and hydroxysafflor yellow A (from Flos Carthami), and paeoniflorin (from Radix Paeoniae Rubra). We quantitatively analyzed their TLR4 antagonistic activities and used the combination index (CI) to quantify their interactions, revealing synergism (CI < 1), additive effects (CI = 1), and antagonism (CI > 1). The results show these agents inhibit nitric oxide (NO) production, with some combinations demonstrating synergistic effects at certain concentrations, while others present antagonistic effects. Understanding these interactions provides a scientific foundation for optimizing TCM formulations, enhancing quality control, efficacy, and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.